NO20030614D0 - Anti-IL-12-antistoffer, sammensetninger, fremgangsmåter og anvendelser - Google Patents
Anti-IL-12-antistoffer, sammensetninger, fremgangsmåter og anvendelserInfo
- Publication number
- NO20030614D0 NO20030614D0 NO20030614A NO20030614A NO20030614D0 NO 20030614 D0 NO20030614 D0 NO 20030614D0 NO 20030614 A NO20030614 A NO 20030614A NO 20030614 A NO20030614 A NO 20030614A NO 20030614 D0 NO20030614 D0 NO 20030614D0
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- compositions
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22335800P | 2000-08-07 | 2000-08-07 | |
US23682700P | 2000-09-29 | 2000-09-29 | |
US09/920,262 US6902734B2 (en) | 2000-08-07 | 2001-08-01 | Anti-IL-12 antibodies and compositions thereof |
PCT/US2001/024720 WO2002012500A2 (en) | 2000-08-07 | 2001-08-07 | Anti-il-12 antibodies, compositions, methods and uses |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20030614D0 true NO20030614D0 (no) | 2003-02-07 |
NO20030614L NO20030614L (no) | 2003-04-02 |
NO330903B1 NO330903B1 (no) | 2011-08-15 |
Family
ID=27397221
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20030614A NO330903B1 (no) | 2000-08-07 | 2003-02-07 | Nukleinsyrer, anti-IL-12-antistoff, sammensetning inneholdende denne samt vertscelle. |
NO2011023C NO2011023I1 (no) | 2000-08-07 | 2011-10-04 | Stelara- Ustekinumab. Ustekinimab er et humant IgG1k monoklonalt antistoff som bindes til p40 proteinsubenheten til human cytokinene IL-12 og IL 23, produsert i en murin myelomcelle ved hjelp av rekombinant DNA teknologi |
NO2020005C NO2020005I1 (no) | 2000-08-07 | 2020-03-11 | ustekinumab. Forlenget SPC |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2011023C NO2011023I1 (no) | 2000-08-07 | 2011-10-04 | Stelara- Ustekinumab. Ustekinimab er et humant IgG1k monoklonalt antistoff som bindes til p40 proteinsubenheten til human cytokinene IL-12 og IL 23, produsert i en murin myelomcelle ved hjelp av rekombinant DNA teknologi |
NO2020005C NO2020005I1 (no) | 2000-08-07 | 2020-03-11 | ustekinumab. Forlenget SPC |
Country Status (33)
Country | Link |
---|---|
US (15) | US6902734B2 (no) |
EP (5) | EP1309692B1 (no) |
JP (4) | JP4731094B2 (no) |
KR (1) | KR100823576B1 (no) |
CN (2) | CN101550190B (no) |
AR (1) | AR030134A1 (no) |
AT (1) | ATE431412T1 (no) |
AU (2) | AU8113701A (no) |
BR (1) | BRPI0113109B8 (no) |
CA (1) | CA2418961C (no) |
CL (1) | CL2009000575A1 (no) |
CY (7) | CY1109149T1 (no) |
DE (2) | DE60138711D1 (no) |
DK (4) | DK3178934T3 (no) |
EA (1) | EA006673B1 (no) |
ES (4) | ES2323760T3 (no) |
FR (1) | FR09C0021I2 (no) |
HK (1) | HK1135991A1 (no) |
HR (1) | HRP20030087B1 (no) |
HU (1) | HU228009B1 (no) |
IL (1) | IL154325A (no) |
LT (6) | LT2090657T (no) |
LU (3) | LU91584I2 (no) |
ME (1) | ME00326B (no) |
MX (1) | MXPA03001229A (no) |
MY (1) | MY133377A (no) |
NL (1) | NL300390I2 (no) |
NO (3) | NO330903B1 (no) |
NZ (2) | NZ535865A (no) |
PT (4) | PT3178934T (no) |
RS (1) | RS50477B (no) |
SI (4) | SI1309692T1 (no) |
WO (1) | WO2002012500A2 (no) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6706264B1 (en) * | 1994-03-14 | 2004-03-16 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y |
US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
US20050249735A1 (en) * | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
US20040018195A1 (en) * | 2002-03-26 | 2004-01-29 | Griswold Don Edgar | Diabetes-related immunoglobulin derived proteins, compositions, methods and uses |
EP1494712A4 (en) * | 2002-03-26 | 2006-06-14 | Centocor Inc | MULTIPLE SCLEROSIS RELATED PROTEINS, COMPOSITIONS, PROCESSES AND APPLICATIONS DERIVED FROM IMMUNOGLOBULIN |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
US7510709B2 (en) * | 2002-10-30 | 2009-03-31 | Genentech, Inc. | Method of treating inflammatory disease by inhibition of IL-17 production |
CA2505325C (en) * | 2002-11-08 | 2014-02-25 | Ablynx N.V. | Stabilized single domain antibodies |
DK2316852T3 (da) * | 2002-11-08 | 2014-06-16 | Ablynx Nv | Stabiliserede enkeltdomæne-antistoffer |
US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
KR20110129988A (ko) * | 2003-07-18 | 2011-12-02 | 암젠 인코포레이티드 | 간세포 성장인자에 결합하는 특이 결합제 |
GB0329146D0 (en) * | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
JP4903061B2 (ja) * | 2004-02-17 | 2012-03-21 | シェーリング コーポレイション | Il−23活性を調節する方法;関連する試薬 |
NZ583153A (en) | 2004-12-21 | 2011-06-30 | Centocor Ortho Biotech Inc | Anti-IL-12 antibodies, epitopes, compositions, methods and uses |
DK1839120T3 (da) | 2004-12-21 | 2013-11-11 | Janssen Biotech Inc | Vektorer baseret på Anti-IL-12-antistoffer, værtsceller og fremgangsmåder til fremstilling og anvendelser |
CN101166763B (zh) * | 2005-04-18 | 2012-09-19 | 伊达研究和发展有限公司 | 稳定的抗乙肝病毒(hbv)抗体配制剂 |
NZ596992A (en) * | 2005-06-30 | 2013-07-26 | Abbott Lab | Il-12/p40 binding proteins |
JP2007172129A (ja) * | 2005-12-20 | 2007-07-05 | Sony Corp | 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム |
AU2007266306A1 (en) * | 2006-05-26 | 2007-12-06 | Apollo Life Sciences Limited | An isolated IL-12 molecule or chimeric molecules thereof |
US20080138833A1 (en) * | 2006-12-07 | 2008-06-12 | Wyeth | Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample |
EP2839743A1 (en) * | 2007-01-16 | 2015-02-25 | Abbvie Inc. | Methods for treating psoriasis |
MX2009010361A (es) | 2007-03-29 | 2009-10-16 | Abbott Lab | Anticuerpos il-12 anti-humanos cristalinos. |
EP2205276A4 (en) * | 2007-09-28 | 2012-08-15 | Janssen Biotech Inc | ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES |
AU2008328785A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
US8557239B2 (en) * | 2009-09-14 | 2013-10-15 | Abbvie Inc. | Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23 |
AU2009225797A1 (en) * | 2008-03-18 | 2009-09-24 | Abbvie Inc. | Methods for treating psoriasis |
MX2010012090A (es) | 2008-05-05 | 2011-04-11 | Novimmune Sa | Anticuerpos anti-il 17 a/il-17f de reactividad cruzada y metodos de uso de los mismos. |
CN104974251A (zh) * | 2008-10-20 | 2015-10-14 | Abbvie公司 | 在抗体纯化过程中的病毒灭活 |
AU2009307735B2 (en) * | 2008-10-20 | 2014-12-04 | Abbvie Inc. | Antibodies that bind to IL-12 and methods of purifying the same |
RU2011126338A (ru) * | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | Стабильные композиции антител и способы их стабилизации |
EP2427203B1 (en) | 2009-05-05 | 2018-10-17 | Novimmune S.A. | Anti-il-17f antibodies and use thereof |
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
ES2862955T3 (es) | 2010-10-01 | 2021-10-08 | Modernatx Inc | Acidos nucleicos manipulados y métodos de uso de los mismos |
TW201309330A (zh) * | 2011-01-28 | 2013-03-01 | Abbott Lab | 包含糖基化抗體之組合物及其用途 |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2013052523A1 (en) | 2011-10-03 | 2013-04-11 | modeRNA Therapeutics | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US20140359902A1 (en) | 2011-12-16 | 2014-12-04 | Synthon Biopharmaceuticals B.V. | EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED |
CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
EP2833920A2 (en) | 2012-04-02 | 2015-02-11 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
MX362705B (es) * | 2012-05-10 | 2019-02-01 | Bioatla Llc | Anticuerpos monoclonales multiespecíficos. |
US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2016036918A1 (en) | 2014-09-03 | 2016-03-10 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
WO2016172359A2 (en) * | 2015-04-24 | 2016-10-27 | The Regents Of The University Of California | Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them |
JP7030689B2 (ja) * | 2015-10-23 | 2022-03-07 | ファイザー インコーポレイティッド | 抗il-2抗体ならびにその組成物及び使用 |
CN109071653A (zh) * | 2016-03-29 | 2018-12-21 | 詹森生物科技公司 | 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣 |
EP3493843A1 (en) | 2016-08-03 | 2019-06-12 | FYB 202 Project GmbH | Production of biosimilar ustekinumab in cho cells |
MX2019005661A (es) | 2016-11-16 | 2019-10-07 | Janssen Biotech Inc | Método para tratar la psoriasis con el anticuerpo específico anti-il23. |
KR20190091325A (ko) | 2016-12-07 | 2019-08-05 | 프로제너티, 인크. | 위장관 검출 방법, 디바이스 및 시스템 |
JP7237834B2 (ja) | 2016-12-14 | 2023-03-13 | ビオラ・セラピューティクス・インコーポレイテッド | 消化管疾病のil-12/il-23阻害薬による治療 |
MX2019008989A (es) | 2017-01-30 | 2019-10-09 | Janssen Biotech Inc | Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa. |
CN110418652A (zh) | 2017-02-07 | 2019-11-05 | 詹森生物科技公司 | 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法 |
US20200199525A1 (en) | 2017-06-08 | 2020-06-25 | Polpharma Biologics S.A. | Improved Methods of Cell Culture |
TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
WO2019106206A1 (en) | 2017-12-01 | 2019-06-06 | Fyb 202 Project Gmbh | Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody |
JP7421500B2 (ja) | 2018-05-18 | 2024-01-24 | ヤンセン バイオテツク,インコーポレーテツド | 抗il12/il23抗体でループスを治療する安全かつ有効な方法 |
TR201808283A2 (tr) * | 2018-06-11 | 2018-07-23 | Centurion Ilac San Ve Tic A S | Sulu farmasöti̇k etenersept bi̇leşi̇mi̇ |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
EP3810268A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
BR112021005467A2 (pt) | 2018-09-24 | 2021-06-22 | Janssen Biotech, Inc. | método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23 |
WO2020106750A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
CN113395979A (zh) | 2018-11-20 | 2021-09-14 | 詹森生物科技公司 | 用抗il-23特异性抗体治疗银屑病的安全且有效的方法 |
AU2020208828A1 (en) | 2019-01-15 | 2021-08-05 | Janssen Biotech, Inc. | Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
EA202192038A1 (ru) | 2019-01-23 | 2021-10-05 | Янссен Байотек, Инк. | Композиции антител к фно для применения в способах лечения псориатического артрита |
CA3133381A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
EP3938391A1 (en) | 2019-03-14 | 2022-01-19 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
EA202192508A1 (ru) | 2019-03-14 | 2022-03-29 | Янссен Байотек, Инк. | Способы получения композиций антитела к фно |
KR20210141583A (ko) * | 2019-03-18 | 2021-11-23 | 얀센 바이오테크 인코포레이티드 | 항-il-12/il-23 항체를 사용한 소아 대상의 건선 치료 방법 |
US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
JP2022535534A (ja) | 2019-06-03 | 2022-08-09 | ヤンセン バイオテツク,インコーポレーテツド | 活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法 |
KR20220029593A (ko) | 2019-06-03 | 2022-03-08 | 얀센 바이오테크 인코포레이티드 | 건선성 관절염의 치료를 위한 항-tnf 항체 조성물, 및 방법 |
CA3145909A1 (en) * | 2019-07-30 | 2021-02-04 | Yu Xia | Anti-human p40 protein domain antibody and use thereof |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
KR20220143005A (ko) | 2019-12-20 | 2022-10-24 | 노바록 바이오테라퓨틱스 리미티드 | 항-인터루킨-23 p19 항체 및 이의 사용 방법 |
WO2022024065A1 (en) * | 2020-07-30 | 2022-02-03 | Janssen Biotech, Inc. | Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody |
US20230040065A1 (en) | 2021-07-09 | 2023-02-09 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
WO2023281463A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
US20240117030A1 (en) | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
US20240059799A1 (en) | 2022-05-11 | 2024-02-22 | Pfizer Inc. | Anti-tl1a antibodies and methods of use thereof |
Family Cites Families (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US122464A (en) | 1872-01-02 | Improvement in cheese-hoops | ||
US941234A (en) | 1909-02-25 | 1909-11-23 | Frank De Clercq | Syrup-percolator. |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
DE3546807C2 (no) | 1985-03-30 | 1991-03-28 | Marc Genf/Geneve Ch Ballivet | |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
GB8517895D0 (en) | 1985-07-16 | 1985-08-21 | Technology Licence Co Ltd | Monoclonal antibodies |
US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
AU610083B2 (en) | 1986-08-18 | 1991-05-16 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
DE3852304T3 (de) | 1987-03-02 | 1999-07-01 | Enzon Lab Inc | Organismus als Träger für "Single Chain Antibody Domain (SCAD)". |
DE3888224T2 (de) | 1987-04-24 | 1994-07-21 | Teijin Ltd | Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung. |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
CA1341235C (en) | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
JP2755395B2 (ja) | 1987-09-23 | 1998-05-20 | ブリストル―マイアーズ スクイブ コムパニー | Hiv感染細胞に殺作用する抗体異種結合体 |
WO1989006283A1 (en) | 1988-01-11 | 1989-07-13 | Ingene (International Genetic Engineering, Inc.) | Novel plasmid vector with pectate lyase signal sequence |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US4987893A (en) | 1988-10-12 | 1991-01-29 | Rochal Industries, Inc. | Conformable bandage and coating material |
US5811523A (en) * | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
JP2893653B2 (ja) | 1988-11-10 | 1999-05-24 | ジェネティックス・インスティテュート・インコーポレイテッド | ナチュラルキラー細胞刺激因子 |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
DE3909708A1 (de) | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
CA2057923A1 (en) | 1989-05-16 | 1990-11-17 | William D. Huse | Co-expression of heteromeric receptors |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
DE10399036I1 (de) | 1989-08-07 | 2004-04-01 | Peptide Technology Ltd | Bindeligande für Tumornekrosisfaktor. |
ATE168416T1 (de) | 1989-10-05 | 1998-08-15 | Optein Inc | Zellfreie synthese und isolierung von genen und polypeptiden |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
EP0433827B1 (en) | 1989-12-22 | 1998-03-04 | F. Hoffmann-La Roche Ag | Cytotoxic lymphocyte maturation factor |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5780597A (en) * | 1989-12-22 | 1998-07-14 | Hoffmann-La Roche Inc. | Monoclonal antibodies to cytotoxic lymphocyte maturation factor |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
TW212184B (no) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
EP0600866B1 (en) | 1990-06-01 | 1997-12-03 | Chiron Corporation | Compositions and methods for identifying biologically active molecules |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
CA2086417C (en) | 1990-06-29 | 1999-07-06 | Biosource Technologies, Inc. | Melanin production by transformed organisms |
US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
AU1435492A (en) | 1991-02-21 | 1992-09-15 | Gilead Sciences, Inc. | Aptamer specific for biomolecules and method of making |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
DE69233367T2 (de) | 1991-04-10 | 2005-05-25 | The Scripps Research Institute, La Jolla | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Hiv感染治療のための異種複合抗体 |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
ES2284226T3 (es) | 1991-07-02 | 2007-11-01 | Nektar Therapeutics | Dispositivo para proporcionar medicamentos en aerosol. |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
ATE249840T1 (de) | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
DE4207475A1 (de) | 1992-03-10 | 1993-09-16 | Goldwell Ag | Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
WO1994008038A1 (en) | 1992-10-02 | 1994-04-14 | Trustees Of Dartmouth College | Bispecific reagents for redirected targeting of low density lipoprotein |
SK279327B6 (sk) | 1992-10-19 | 1998-10-07 | Dura Pharmaceuticals | Zariadenie na vytváranie aerosolu z práškového lie |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
WO1994016970A1 (en) | 1993-01-19 | 1994-08-04 | Glaxo Group Limited | Device |
US5300478A (en) * | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
JP3824633B2 (ja) | 1993-02-12 | 2006-09-20 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニアー・ユニバーシティ | 標的遺伝子の調節的転写および他の生物学的結果 |
US5770428A (en) | 1993-02-17 | 1998-06-23 | Wisconsin Alumni Research Foundation | Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site |
EP0614989A1 (en) | 1993-02-17 | 1994-09-14 | MorphoSys AG | A method for in vivo selection of ligand-binding proteins |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0652227T3 (da) * | 1993-04-30 | 1998-12-21 | Tt Pharmaceuticals Inc | Fremgangsmåde til oprensning af et hydrofobt polypeptid |
DE4315127A1 (de) * | 1993-05-07 | 1994-11-10 | Behringwerke Ag | Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12 |
CA2125763C (en) * | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
DE4337197C1 (de) | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
SE9304060D0 (sv) | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Sätt att selektera specifika bakteriofager |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
WO1995024220A1 (en) | 1994-03-07 | 1995-09-14 | Medarex, Inc. | Bispecific molecules having clinical utilities |
ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
EP0804581B1 (en) | 1994-04-22 | 2001-09-26 | Corixa Corporation | Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production |
US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US5891680A (en) * | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6037453A (en) | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
EP1709970A1 (en) * | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5853697A (en) | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
CN1213974A (zh) | 1996-01-03 | 1999-04-14 | 葛兰素集团有限公司 | 吸入器具 |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
DE19624387C2 (de) | 1996-06-19 | 1999-08-19 | Hatz Motoren | Kaltstartvorrichtung |
ATE210682T1 (de) | 1996-09-03 | 2001-12-15 | Gsf Forschungszentrum Umwelt | Zerstörung von kontaminierenden tumorzellen in stammzelltransplantaten mit bispezifischen antikörpern |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
AU6150498A (en) | 1997-02-07 | 1998-08-26 | Wistar Institute, The | Methods and compositions for the inhibition of interleukin-12 production |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
US6060284A (en) * | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
EP1049717B1 (en) * | 1998-01-23 | 2007-03-21 | F. Hoffmann-La Roche Ag | Antibodies against human il-12 |
ATE305506T1 (de) | 1998-12-09 | 2005-10-15 | Protein Design Labs Inc | Verwendung von il-12 antikörpern zur behandlung von psoriasis |
US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
TR200603997T1 (tr) | 1999-03-25 | 2010-01-21 | Abbott Gmbh & Co. Kg | Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler. |
WO2001019373A2 (en) | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
EP1506302A4 (en) | 2002-05-23 | 2006-02-08 | Cognis Ip Man Gmbh | CANDIDA TROPICALIS BLOCKED BY OXIDATION BETA NON REVERSIBLE |
DE102007030072A1 (de) | 2007-06-29 | 2009-01-02 | BSH Bosch und Siemens Hausgeräte GmbH | Elektrischen Antriebseinrichtung für ein Wasserführendes Haushaltsgerät |
JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
JP5155355B2 (ja) | 2010-04-07 | 2013-03-06 | レノボ・シンガポール・プライベート・リミテッド | 無線基地局の自律的な負荷調整が可能な無線端末装置 |
US9619256B1 (en) | 2012-06-27 | 2017-04-11 | EMC IP Holding Company LLC | Multi site and multi tenancy |
JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
US9205258B2 (en) | 2013-11-04 | 2015-12-08 | ElectroCore, LLC | Nerve stimulator system |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2001
- 2001-08-01 US US09/920,262 patent/US6902734B2/en not_active Expired - Lifetime
- 2001-08-07 DK DK17153336.7T patent/DK3178934T3/da active
- 2001-08-07 IL IL154325A patent/IL154325A/en active Protection Beyond IP Right Term
- 2001-08-07 EA EA200300137A patent/EA006673B1/ru not_active IP Right Cessation
- 2001-08-07 RS YUP-93/03A patent/RS50477B/sr unknown
- 2001-08-07 BR BRPI0113109A patent/BRPI0113109B8/pt active IP Right Grant
- 2001-08-07 MY MYPI20013706 patent/MY133377A/en unknown
- 2001-08-07 NZ NZ535865A patent/NZ535865A/en not_active IP Right Cessation
- 2001-08-07 SI SI200130913T patent/SI1309692T1/sl unknown
- 2001-08-07 KR KR1020037001843A patent/KR100823576B1/ko active Protection Beyond IP Right Term
- 2001-08-07 AU AU8113701A patent/AU8113701A/xx active Pending
- 2001-08-07 DE DE60138711T patent/DE60138711D1/de not_active Expired - Lifetime
- 2001-08-07 EP EP01959598A patent/EP1309692B1/en not_active Expired - Lifetime
- 2001-08-07 EP EP09006396.7A patent/EP2090657B1/en not_active Expired - Lifetime
- 2001-08-07 ES ES01959598T patent/ES2323760T3/es not_active Expired - Lifetime
- 2001-08-07 SI SI200131066T patent/SI2305817T1/en unknown
- 2001-08-07 CA CA002418961A patent/CA2418961C/en not_active Expired - Lifetime
- 2001-08-07 HU HU0302378A patent/HU228009B1/hu active Protection Beyond IP Right Term
- 2001-08-07 DK DK09006396.7T patent/DK2090657T3/en active
- 2001-08-07 AR ARP010103780A patent/AR030134A1/es active IP Right Grant
- 2001-08-07 ES ES09006396.7T patent/ES2624502T3/es not_active Expired - Lifetime
- 2001-08-07 NZ NZ524145A patent/NZ524145A/en not_active IP Right Cessation
- 2001-08-07 CN CN200810100025.3A patent/CN101550190B/zh not_active Expired - Lifetime
- 2001-08-07 CN CNA018169619A patent/CN1468309A/zh active Pending
- 2001-08-07 ES ES10184116.1T patent/ES2647220T3/es not_active Expired - Lifetime
- 2001-08-07 PT PT171533367T patent/PT3178934T/pt unknown
- 2001-08-07 WO PCT/US2001/024720 patent/WO2002012500A2/en active IP Right Grant
- 2001-08-07 PT PT101841161T patent/PT2305817T/pt unknown
- 2001-08-07 ES ES17153336T patent/ES2747573T3/es not_active Expired - Lifetime
- 2001-08-07 DE DE122009000025C patent/DE122009000025I1/de active Pending
- 2001-08-07 AU AU2001281137A patent/AU2001281137B2/en active Active
- 2001-08-07 EP EP10184116.1A patent/EP2305817B1/en not_active Expired - Lifetime
- 2001-08-07 EP EP17153336.7A patent/EP3178934B1/en not_active Expired - Lifetime
- 2001-08-07 DK DK01959598T patent/DK1309692T3/da active
- 2001-08-07 ME MEP-2008-444A patent/ME00326B/me unknown
- 2001-08-07 AT AT01959598T patent/ATE431412T1/de active
- 2001-08-07 LT LTEP09006396.7T patent/LT2090657T/lt unknown
- 2001-08-07 LT LTEP10184116.1T patent/LT2305817T/lt unknown
- 2001-08-07 LT LTEP17153336.7T patent/LT3178934T/lt unknown
- 2001-08-07 PT PT01959598T patent/PT1309692E/pt unknown
- 2001-08-07 JP JP2002517788A patent/JP4731094B2/ja not_active Expired - Lifetime
- 2001-08-07 SI SI200131060A patent/SI2090657T1/sl unknown
- 2001-08-07 EP EP19179253.0A patent/EP3597752A1/en not_active Withdrawn
- 2001-08-07 DK DK10184116.1T patent/DK2305817T3/en active
- 2001-08-07 PT PT90063967T patent/PT2090657T/pt unknown
- 2001-08-07 MX MXPA03001229A patent/MXPA03001229A/es active IP Right Grant
- 2001-08-07 SI SI200131070T patent/SI3178934T1/sl unknown
-
2003
- 2003-02-07 HR HRP20030087AA patent/HRP20030087B1/xx not_active IP Right Cessation
- 2003-02-07 NO NO20030614A patent/NO330903B1/no not_active IP Right Cessation
-
2004
- 2004-08-06 US US10/912,994 patent/US20050002937A1/en not_active Abandoned
- 2004-10-28 US US10/975,740 patent/US7063964B2/en not_active Expired - Lifetime
- 2004-10-28 US US10/975,883 patent/US7279157B2/en not_active Expired - Lifetime
- 2004-10-28 US US10/975,708 patent/US7166285B2/en not_active Expired - Lifetime
-
2007
- 2007-01-29 US US11/668,256 patent/US7560247B2/en not_active Expired - Lifetime
-
2009
- 2009-03-11 CL CL2009000575A patent/CL2009000575A1/es unknown
- 2009-05-13 NL NL300390C patent/NL300390I2/nl unknown
- 2009-05-13 FR FR09C0021C patent/FR09C0021I2/fr active Active
- 2009-05-15 LT LTPA2009002C patent/LTC1309692I2/lt unknown
- 2009-06-09 CY CY20091100601T patent/CY1109149T1/el unknown
- 2009-06-12 CY CY2009007C patent/CY2009007I2/el unknown
- 2009-07-09 US US12/500,120 patent/US7887807B2/en not_active Expired - Fee Related
- 2009-07-10 LU LU91584C patent/LU91584I2/fr unknown
-
2010
- 2010-01-05 HK HK10100042.6A patent/HK1135991A1/zh not_active IP Right Cessation
- 2010-12-17 US US12/971,626 patent/US8084233B2/en not_active Expired - Fee Related
-
2011
- 2011-03-10 JP JP2011052971A patent/JP2011173884A/ja not_active Withdrawn
- 2011-10-04 NO NO2011023C patent/NO2011023I1/no not_active IP Right Cessation
- 2011-10-26 JP JP2011235204A patent/JP2012025779A/ja active Pending
- 2011-11-18 US US13/299,874 patent/US8329171B2/en not_active Expired - Lifetime
-
2012
- 2012-11-07 US US13/670,918 patent/US8703141B2/en not_active Expired - Fee Related
-
2014
- 2014-02-26 US US14/190,893 patent/US9409984B2/en not_active Expired - Lifetime
- 2014-09-22 JP JP2014192690A patent/JP6076303B2/ja not_active Expired - Lifetime
-
2016
- 2016-06-30 US US15/198,678 patent/US9676848B2/en not_active Expired - Lifetime
-
2017
- 2017-05-01 US US15/583,487 patent/US10259867B2/en not_active Expired - Fee Related
- 2017-05-18 CY CY20171100525T patent/CY1118901T1/el unknown
- 2017-12-05 CY CY20171101269T patent/CY1119650T1/el unknown
-
2018
- 2018-03-19 CY CY2018010C patent/CY2018010I2/el unknown
- 2018-03-20 LT LTPA2018007C patent/LTC2305817I2/lt unknown
- 2018-03-20 LU LU00066C patent/LUC00066I2/fr unknown
-
2019
- 2019-02-25 US US16/284,316 patent/US10519231B2/en not_active Expired - Fee Related
- 2019-10-02 CY CY20191101021T patent/CY1122505T1/el unknown
- 2019-11-07 US US16/677,120 patent/US11078267B2/en not_active Expired - Lifetime
-
2020
- 2020-01-10 LU LU00145C patent/LUC00145I2/fr unknown
- 2020-01-13 LT LTPA2020001C patent/LTPA2020001I1/lt unknown
- 2020-01-16 CY CY2020003C patent/CY2020003I1/el unknown
- 2020-03-11 NO NO2020005C patent/NO2020005I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTC2305817I2 (lt) | Anti-IL-12 antikūnai, kompozicijos, būdai ir panaudojimas | |
CY2019029I2 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
DK1390389T3 (da) | Cripto-blokerende antistoffer og anvendelser deraf | |
CY2014038I2 (el) | Αντι-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
NO20055018D0 (no) | Anti-amyolide antistoffer, sammensetninger, fremgangsmater og anvendelser | |
NO20055568D0 (no) | Substituerte 1,4-diazepiner og anvendelser derav | |
DK1278763T3 (da) | 3-Nitrogen-6,7-dioxygensteroider og anvendelser relateret dertil | |
AU2002359495A8 (en) | Anti-tnf antibodies, compositions, methods and uses | |
EE200300569A (et) | CD44v6-spetsiifilised antikehad | |
NO20024105L (no) | Memnopeptider, fremgangsmåte for deres fremstilling og anvendelse av disse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: STELARA; NAT. REG. NO/DATE: EU/1/08/494/003 OG 004 20100415; FIRST REG. NO/DATE: EU , EU/1/08/494/001 20090116 Spc suppl protection certif: 2011023 Filing date: 20111004 |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: JANSSEN BIOTECH, US |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: STELARA; NAT. REG. NO/DATE: EU/1/08/494/003 OG 004 20100415; FIRST REG. NO/DATE: EU , EU/1/08/494/001 20090116 Spc suppl protection certif: 2011023 Filing date: 20111004 Extension date: 20240116 |
|
SPCK | Change in the validity period of an spc |
Free format text: PRODUCT NAME: STELARA- USTEKINUMAB. USTEKINIMAB ER ET HUMANT IGG1K MONOKLONALT ANTISTOFF SOM BINDES TIL P40 PROTEINSUBENHETEN TIL HUMAN CYTOKINENE IL-12 OG IL 23, PRODUSERT I EN MURIN MYELOMCELLE VED HJELP AV REKOMBINANT DNA TEKNOLOGI.; NAT. REG. NO/DATE: EU/1/08/494/003 OG 004 20100415; FIRST REG. NO/DATE: EU/1/08/494/001 20090116 Spc suppl protection certif: 2011023 Filing date: 20111004 Extension date: 20240120 |
|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: USTEKINUMAB. FORLENGET SPC; NAT. REG. NO/DATE: 004 20100415; FIRST REG. NO/DATE: 002 20090120 Spc suppl protection certif: 2020005 Filing date: 20200311 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: USTEKINUMAB; NAT. REG. NO/DATE: 004 20100415; FIRST REG. NO/DATE: 002 20090120 Spc suppl protection certif: 2020005 Filing date: 20200311 Extension date: 20240720 |
|
MK1K | Patent expired | ||
SPCX | Expiry of an spc |
Spc suppl protection certif: 2011023 |